Granulocyte colony-stimulating factor utilization postautologous hematopoietic stem cell transplant in multiple myeloma patients: Does one size fit all?

Abstract

Purpose

To evaluate a single institution’s experience with granulocyte colony-stimulating factor after autologous hematopoietic stem cell transplant in myeloma patients to identify populations that benefit most from granulocyte colony-stimulating factor administration.

Methods

Retrospective chart reviews were conducted on patients 18+ years with multiple myeloma that underwent autologous hematopoietic stem cell transplant at UW Health from January 2012 to May 2016. Data collection included demographics, length of stay, time to engraftment, Eastern Cooperative Oncology Group performance status score, and hematopoietic cell transplantation-comorbidity index. The primary outcome was days from transplant to engraftment, defined as absolute neutrophil count > 500/mm³ for two consecutive days or absolute neutrophil count > 1000/mm³ once. A subset analysis was performed on patients whose date of engraftment was known.

Results

In total, 216 individual patients were included in the full cohort and 122 patients included in the subset analysis. Median time to engraftment between patients administered granulocyte colony-stimulating factor and the nongranulocyte colony-stimulating factor group was 12 versus 19 days (P < 0.001) in the full cohort and 12 versus 14 days (P < 0.001) in the subset analysis. The average length of stay posthematopoietic stem cell transplant in the granulocyte colony-stimulating factor group was 15 days versus 17 days in the nongranulocyte colony-stimulating factor group (P = 0.026) in the subset analysis. Additionally, no difference in time to engraftment was seen when stratified by age, Eastern Cooperative Oncology Group performance status score, or hematopoietic cell transplantation-comorbidity index.

Conclusion

Our study supports use of granulocyte colony-stimulating factor posthematopoietic stem cell transplant in myeloma patients to decrease time to engraftment and length of stay. Consideration should be given to utilization in all patients in this population posthematopoietic stem cell transplant. Further research is needed to identify the populations that benefit most from granulocyte colony-stimulating factor administration.

Keywords

Granulocyte colony-stimulating factor growth factor multiple myeloma autologous stem cell transplant

Get full access to this article

View all access options for this article.

References

Copelan

. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813–1826. DOI: 10.1056/NEJMra052638.

Garcia

. Role of hematopoietic stem cell transplantation in multiple myeloma. Clin Lymphoma Myeloma Leuk 2015; 15: 86–91. 2014/07/14. DOI: 10.1016/j.clml.2014.07.007.

Gyurkocza

Sandmaier

. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 2014; 124: 344–353. 2014/06/09. DOI: 10.1182/blood-2014-02-514778.

Moreau

Touzeau

. Initial treatment of transplant candidates with multiple myeloma. Semin Oncol 2013; 40: 585–591. DOI: 10.1053/j.seminoncol.2013.07.006.

Gertz

Gastineau

Lacy

et al.

SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. Bone Marrow Transplant 2011; 46: 956–961. 2010/10/25. DOI: 10.1038/bmt.2010.233.

Kolaczkowska

Kubes

. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013; 13: 159–175. DOI: 10.1038/nri3399.

Trivedi

Martinez

Corringham

et al.

Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant 2009; 43: 895–908. 2009/04/13. DOI: 10.1038/bmt.2009.75.

Smith

Bohlke

Lyman

et al.

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33: 3199–3212. 2015/07/13. DOI: 10.1200/JCO.2015.62.3488.

Crawford

Becker

Armitage

et al.

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017; 15: 1520–1541. DOI: 10.6004/jnccn.2017.0175.

10.

Teva. Granix (prescribing information), (2014).

11.

Gertz

Ansell

Dingli

et al.

Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 2008; 83: 1131–1138. DOI: 10.4065/83.10.1131.

12.

Dettenkofer

Ebner

Bertz

et al.

Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. Bone Marrow Transplant 2003; 31: 795–801. DOI: 10.1038/sj.bmt.1703920.

13.

Elayan

Horowitz

Magraner

et al.

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant 2015; 21: 1921–1925. 2015/05/30. DOI: 10.1016/j.bbmt.2015.05.024.